Abstract: Provided is a functional edible oil (FEO), a preparation method therefor and use thereof. The FEO is prepared by ternary transesterification of medium-chain triglycerides (MCTs), oils rich in linoleic acid, and oils rich in linolenic acid. The fatty acid composition and distribution of the FEO were determined and optimized via comparative analysis of indexes such as melting point, and effect of improving glucose and lipid metabolism as determined by animal tests. The FEO has a mass ratio of 2.3 to 4.0 for medium chain fatty acids (MCFAs) in MCTs to long chain fatty acids (LCFAs) in the oils rich in linoleic acid, and oils rich in linolenic acid and a mass ratio of 0.5 to 1.0 for linoleic acid to linolenic acid in the LCFAs, by mass of fatty acids. The FEO is added to food products at ?18.00%.

Abstract: Disclosed is a base oil for functional food oils and fats, a preparation method therefor and the use thereof. The base oil for functional food oils and fats is formed through ternary transesterification on medium-chain triglycerides, high-melting-point fat and oils rich in linolenic acid. The base oil for functional food oils and fats has a wide melting range, can significantly improve the glucose and lipid metabolism disorder, balance the essential and functional fatty acids in the body, and quickly replenish energy. Animal experiments were conducted and the fatty acid composition and distribution of the base oil were optimized and determined through comparative analysis based on evaluation indicators such as the improved effect in glucose and lipid metabolism and melting point.

Abstract: The use of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone in the preparation of a drug for treating peripheral T-cell lymphoma (PTCL). The PTCL is preferably treatment-naïve PTCL. Other first-line and second-line drugs for treating PTCL may also be further used on the basis of the foregoing. A method for treating PTCL, the method comprising administering, to a patient, a therapeutically effective amount of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone. The combined administration of the drugs is safe and tolerable, has a small toxicity and few side effects, and can obtain a higher total objective remission rate (ORR) in treatment-naïve PTCL patients.

Abstract: The present invention provides use of mitoxantrone hydrochloride liposome and pegaspargase in preparation of drug for treating NK/T-cell lymphoma (NKTCL). The NKTCL comprises initial-treating, relapsed, and refractory extranodal NKTCL. Preferably, the initial-treating, relapsed, and refractory extranodal NKTCL is initial-treating, relapsed, and refractory extranodal nasal NKTCL. On this basis, other first-line and second-line drugs for treating NKTCL can also be further used. The present invention further provides a method for treating NKTCL. The method relates to administering therapeutically effective amounts of mitoxantrone hydrochloride liposome and pegaspargase to a patient. The mitoxantrone hydrochloride liposome improves the curative effect of pegaspargase on NKTCL, has little toxic and side effects, and increases the complete response rate (CR rate) and the partial response rate (PR rate) of diseases.